Does Modified 5‐Item Frailty Index Correlate With Survival in Oropharyngeal Squamous Cell Carcinoma?
Head & Neck · 2026
DOI: 10.1002/hed.70005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2026. Verfasst von Marta Chmielecka und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Frailty, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Oracle Cancer Trust, Cancer Research UK.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Introduction
Oropharyngeal squamous cell cancer (OPSCC) is a common subtype of head and neck cancer. It is generally stratified into high, intermediate, and low risk prognostic groups on the basis of HPV (human papillomavirus) status and smoking history (Ang risk stratification). Frailty has been shown to have a negative survival effect in head and neck cancer. The effect of frailty on survival in OPSCC is unknown. The aim of this study was to explore overall survival (OS) and disease‐specific survival (DSS) in OPSCC based on the modified 5‐item frailty index (mFI‐5).
Methods
This was a retrospective cohort study of patients diagnosed with OPSCC in the West of Scotland. The mFI‐5 is a validated score that categorizes patients according to their level of frailty. Univariate and multivariate survival analyses were performed.
Results
One thousand and one patients with OPSCC diagnosed between 2012 and 2020 were identified. The median OS was shortened in both the 'Moderately Frail' (39 months) and 'Severely Frail' groups (11 months) compared with the 'Not Frail' group (82 months) ( p < 0.001). DSS was shorter in the'Severely Frail' group (16 months) compared with the'Moderately Frail' group (66 months) ( p < 0.001). However, after adjustment for other characteristics including HPV and PS (World Health Organization/Eastern Cooperative Oncology Group Performance Status), frailty was not significant on multivariate analysis.
Conclusion
Survival in patients with OPSCC decreases significantly with increasing frailty as measured by the mFI‐5. However, PS and HPV status are better predictors of OS and DSS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK.
- School of Cancer Sciences, Garscube Estate, University of Glasgow, Glasgow, UK.
- Glasgow Head and Neck Cancer (GLAHNC) Research Group, Glasgow, UK.
- Department of Otolaryngology/Head and Neck Surgery, Glasgow Royal Infirmary and Queen Elizabeth University Hospital, Glasgow, UK.
- Department of Otolaryngology, Forth Valley Royal Hospital, NHS Forth Valley, Larbert, UK.
- Academic Department of General Surgery, Glasgow Royal Infirmary, Glasgow, UK.
ORCID-Profile: Rhona Hurley, Nichola Philp, Matthew Donachie, Josh McGovern, Katrina Knight, Nicholas J W Rattray
Förderung
- Oracle Cancer Trust
- Cancer Research UK
Zitieren
APA
Chmielecka, M., Hurley, R., Slim, M. A. M., Philp, N., Donachie, M., Horackiewicz, J., McGovern, J., Knight, K., Rattray, N. J. W., Paterson, C., & Douglas, C. M. (2026). Does Modified 5‐Item Frailty Index Correlate With Survival in Oropharyngeal Squamous Cell Carcinoma?. Head & Neck. https://doi.org/10.1002/hed.70005
Vancouver
Chmielecka M, Hurley R, Slim MAM, Philp N, Donachie M, Horackiewicz J, et al. Does Modified 5‐Item Frailty Index Correlate With Survival in Oropharyngeal Squamous Cell Carcinoma?. Head & Neck. 2026. doi:10.1002/hed.70005
BibTeX
@article{Chmielecka2026,
author = {Chmielecka, Marta and Hurley, Rhona and Slim, Mohd Afid Mohd and Philp, Nichola and Donachie, Matthew and Horackiewicz, Jan and McGovern, Josh and Knight, Katrina and Rattray, Nicholas J W and Paterson, Claire and Douglas, Catriona M},
title = {Does Modified 5‐Item Frailty Index Correlate With Survival in Oropharyngeal Squamous Cell Carcinoma?},
journal = {Head & Neck},
year = {2026},
doi = {10.1002/hed.70005}
}
EUVIMED